"Tauopathies" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Neurodegenerative disorders involving deposition of abnormal tau protein isoforms (TAU PROTEINS) in neurons and glial cells in the brain. Pathological aggregations of tau proteins are associated with mutation of the tau gene on chromosome 17 in patients with ALZHEIMER DISEASE; DEMENTIA; PARKINSONIAN DISORDERS; progressive supranuclear palsy (SUPRANUCLEAR PALSY, PROGRESSIVE); and corticobasal degeneration.
| Descriptor ID |
D024801
|
| MeSH Number(s) |
C10.574.945
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Tauopathies".
Below are MeSH descriptors whose meaning is more specific than "Tauopathies".
This graph shows the total number of publications written about "Tauopathies" by people in this website by year, and whether "Tauopathies" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2006 | 2 | 0 | 2 |
| 2011 | 3 | 0 | 3 |
| 2012 | 1 | 0 | 1 |
| 2013 | 2 | 0 | 2 |
| 2014 | 3 | 0 | 3 |
| 2015 | 1 | 0 | 1 |
| 2016 | 4 | 0 | 4 |
| 2017 | 1 | 1 | 2 |
| 2018 | 1 | 1 | 2 |
| 2020 | 1 | 1 | 2 |
| 2021 | 6 | 0 | 6 |
| 2022 | 2 | 0 | 2 |
| 2023 | 3 | 0 | 3 |
| 2024 | 4 | 1 | 5 |
| 2025 | 3 | 1 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Tauopathies" by people in Profiles.
-
Phosphorylation at serine 214 correlates with tau seeding activity in an age-dependent manner in two mouse models for tauopathies and is required for tau transsynaptic propagation. J Alzheimers Dis. 2025 Oct; 107(4):1706-1720.
-
Distinct systemic impacts of A?42 and Tau revealed by whole-organism snRNA-seq. Neuron. 2025 Jul 09; 113(13):2065-2082.e8.
-
Inhibition of soluble epoxide hydrolase confers neuroprotection and restores microglial homeostasis in a tauopathy mouse model. Mol Neurodegener. 2025 Apr 23; 20(1):44.
-
Inhaled xenon modulates microglia and ameliorates disease in mouse models of amyloidosis and tauopathy. Sci Transl Med. 2025 Jan 15; 17(781):eadk3690.
-
In vivo hyperphosphorylation of tau is associated with synaptic loss and behavioral abnormalities in the absence of tau seeds. Nat Neurosci. 2025 Feb; 28(2):293-307.
-
TYK2 regulates tau levels, phosphorylation and aggregation in a tauopathy mouse model. Nat Neurosci. 2024 Dec; 27(12):2417-2429.
-
Protocol for the isolation and proteomic analysis of?pathological tau-seeds. STAR Protoc. 2024 09 20; 5(3):103185.
-
MAPT H2 haplotype and risk of Pick's disease in the Pick's disease International Consortium: a genetic association study. Lancet Neurol. 2024 May; 23(5):487-499.
-
TMEM106B coding variant is protective and deletion detrimental in a mouse model of tauopathy. Acta Neuropathol. 2024 03 25; 147(1):61.
-
TFEB-vacuolar ATPase signaling regulates lysosomal function and microglial activation in tauopathy. Nat Neurosci. 2024 Jan; 27(1):48-62.